HSP90在胰腺癌组织芯片中的表达及临床意义

Expression and Clinical Significance of HSP90 in Pancreatic Carcinoma Using Tissue Microarray

目的用组织芯片技术探讨胰腺癌组织中HSP90蛋白的表达及其与胰腺癌临床病理特征和预后的相关性及意义。方法将88例胰腺癌组织和11例正常胰腺组织制成组织芯片，采用EnVision免疫组化方法检测HSP90蛋白在胰腺癌中的表达，并对随访2个月～6年的53例病例作了生存分析。结果胰腺癌中HSP90高表达为65例（73．9％）。HSP90表达和胰腺癌的临床TNM分期晚、淋巴结转移存在相关性（P〈0．01），与肿瘤病理分级、部位和大小无关（P〈0．05）。在有随访结果的53例病例中，单因素Cox分析显示，HSP90表达与预后无关（P〉0．05）。结论HSP90在胰腺癌中过表达可能参与了胰腺癌的发生、发展和转移。HSP90不是胰腺癌有意义的预后指标。

Objective To investigate the expression of HSP90 in pancreatic ductal adenocacinoma （PDAC） by tissue microarray technique,as well as its relationship with the clinicopathoiogic features,in addition,the prognostic significance of HSP90 expression in PDAC.Methods The pancreatic cancer tissue microarray was composed of 88 specimens of the pancreatic adenocarcinoma and 11 normal pancreatic tissues as control subject.EnVision immunohistochemistry was performed to examine expressions of HSP90.In addition,53 of the 88 cases were follow-up from 2 months to 6 years,in which the survival was analyzed.Results High expression of HSP90 in tumors was showed 65 （73.9%）.The expression of HSP90 was significantly associated with late TNM stage and lymph node metastasis（P〈0.01）,but no distinct difference was found in tumor location,size and pathologic grade （P〉0.05）.Univariate analysis revealed that HSP90 is not a prognosticator for PDAC （P〉0.05）.Conclusion The pathogenesis,development and metastasis of pancreatic cancer is associated with HSP90.The expression of HSP90 is not a significant prognostic indicator for PDAC.